Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06155214
Other study ID # DRDTIT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 30, 2023
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source Children's Hospital of Chongqing Medical University
Contact Li Chen, doctor
Phone 13677620103
Email chenli2012@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The incidence rate of developmental regression is gradually increasing. In the early stages of children's development, both ASD and DD patients can experience developmental regression, which in turn aggravates cognitive function impairment and seriously affects the effectiveness of intervention and treatment. However, the mechanism is unclear, and early screening and diagnosis are difficult. At present, the etiological mechanism of regressive autism and retardation patients at home and abroad is still unclear.This study will advance knowledge about the biological neurocognitive processes, clinical course and outcomes with the potential to improve child and family outcomes through earlier recognition and support. Based on the previous research foundation and advantages of team members, this young innovation team intends to further improve early disease screening, diagnosis strategies, and scientific typing plans by conducting basic and clinical collaborative research on the pathogenesis, precise typing biomarkers, and intervention treatment targets of children with major developmental regression related diseases, and to search for possible gene and drug intervention targets.


Description:

1. Procedures. Children who visited the Children's Health Department between 2021.12 and 2024.12., met the inclusion criteria, and had informed consent signed by their parents. Developmental assessment (Gesell assessment, ABC scale) was routinely performed upon enrollment. After enrollment, routine follow-up visits will be conducted every three months for 1-2 hours each time. Clinicians and researchers will carefully sort out the subject's development process, record and evaluate it. If regression occurs, retest developmental assessment (Gesell assessment, ABC questionnaire). Behavioral assessments and blood samples will be collected once for those found to be regressed upon enrollment. The team will conduct biomarker, genomics, and imaging research based on a prospective patient study cohort. 2. Sample size.This study is a observational trial. 100 children with autism spectrum disorder who met the inclusion criteria and signed informed consent forms were included. Among them, there are 30 cases of children with regressive autism spectrum disorder. 100 children with global developmental delay who met the inclusion criteria and signed informed consent forms were included. Among them, there are 30 cases of children with global developmental delay.And 100 normally developing children. Tools used in the research process: (Gesell assessment, ABC questionnaire). 3. Statistical analysis.All the data are analyzed using SPSS 25.0 or R language,which enters by a dedicated person,and checks by three people to ensure accurate data entry.Statistical analysis is completed under the guidance of professional statistical analysts from the Epidemiology Research Office of the project leader's unit. 4. Ethical matters and data protection. Before epidemiological survey,children and guardians participating in the study signed a consent form and schools signed a disclaimer.During the study,medical ethics laws and regulations were strictly observed,and psychiatrists,psychologists and pediatricians participated in the entire process to provide health protection for children.And they protect the privacy of subjects and do not disclose subjects' information.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year to 7 Years
Eligibility Inclusion Criteria: - (1)ASD patients: 1. Patients diagnosed with autism spectrum disorder based on DSM-5 by 2 child care physicians and/or psychiatrists with associate senior professional titles or above. 2. Aged 1-7years - (2)DDpatients: 1. Patients diagnosed with global developmental delay based on DSM-5 by 2 child care physicians and/or psychiatrists with associate senior professional titles or above. 2. Aged 1-7 years Exclusion Criteria: - Exclude other histories of mental illness, neurological diseases and severe physical diseases, exclude patients with a history of substance and drug abuse, and patients who have not taken risperidone and other related antipsychotic drugs.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Growth,Development and Mental Health of Children and Adolescents Center Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Chen Li

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in the Gesell Developmental Scale(GDS). Children are followed up every 6 months, and at each follow-up point, the GDS is used to assess children and obtain their comprehensive scores in various developmental domains. These domains may include motor development, gross and fine motor coordination, language and communication, cognitive and thinking abilities. The score range for language development is 0-100, where a higher score indicates a more excellent level of development in the field, in line with age expectations, while a lower score may indicate a lag or issues in the development of that field. 2 years
Primary Changes in Infants-Junior High School Students'Social Development Screening Test. The scores obtained from the Infant to Middle School Student Social Life Skills Scale (S-M) at each 3-month follow-up reflect the social interaction, communication skills, and adaptation to social environments of the participants at different follow-up stages. The score range for the Infants-Junior High School Students' Social Development Screening Test varies depending on the specific assessment tool used. Generally, the scores may range from 0 to 100 or may be presented in percentile ranks. In general, a higher score indicates that the individual's social development is more advanced and aligned with age expectations. On the other hand, a lower score might suggest developmental lags or challenges in social skills. 2 years
Primary Changes in Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV). Conducting follow-up assessments every 6 months using the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV) scores reflect the cognitive and intellectual development of children at different follow-up points. The total score range of WISC-IV is in percentage (from 0 to 100), where higher scores indicate stronger abilities in the corresponding domains. 2 years
Primary Changes in Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) . Conducting follow-up assessments every 6 months using the Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) scores reflect the cognitive and intellectual development of children at different follow-up points. The total score range of WPPSI-IV is in percentage (from 0 to 100), where higher scores indicate stronger abilities in the corresponding domains. 2 years
Primary Changes in Child Behavior Checklist (CBCL). Conducting follow-up assessments every 3 months using the Child Behavior Checklist (CBCL) scores reflects the emotional and behavioral issues of children at different follow-up points.The scores on the CBCL typically range from 0 to 100, and higher scores may indicate that children are experiencing difficulties in behavior and emotional problems. 2 years
Primary Changes in Questionnaire-Children with Difficulties. Follow-up assessments every 3 months, using the Questionnaire-Children with Difficulties (QCD) scores, reflect children's psychological issues and behavioral difficulties. The scoring range of the QCD questionnaire may vary depending on the specific version or rating system. For example, certain rating systems may categorize scores into levels of severity such as mild, moderate, or severe difficulties. Higher scores may indicate higher levels of psychological difficulties or disorders. Conversely, lower scores may suggest fewer problems or mild manifestations. 2 years
Primary Changes in Dream-Infant-Toddler Language Communication Screening(DREAM-IT-S). The scores obtained from the Dream-Infant-Toddler Language Communication Screening (DREAM-IT-S) administered at each 3-month follow-up reflect the language abilities of children.The total score range of DREAM-IT-S is between 0 and 10, where a lower score indicates better language communication ability, while a higher score suggests potential delays or obstacles in language development. 2 years
Primary Changes in Dreaming Children's Language Standardized Assessment (DREAM-C). The scores obtained from the Dream-Infant-Toddler Language Communication Screening (DREAM-IT-S) and Dreaming Children's Language Standardized Assessment (DREAM-C) administered at each 3-month follow-up reflect the language abilities of children. The total score range of DREAM-C can vary depending on the specific assessment criteria, but it typically falls within a predetermined range. The exact range depends on the design of the assessment tool and scoring system, but generally, it may be scored on a scale from 0 to 100 or other values. Lower scores indicate stronger language abilities and effective communication skills, while higher scores may suggest potential language development delays or communication barriers. 2 years
See also
  Status Clinical Trial Phase
Completed NCT02847182 - Cord Blood Infusion for Children With Autism Spectrum Disorder Phase 2
Completed NCT02708290 - Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Completed NCT04771338 - Examining the Effects of a Job Entry Intervention N/A
Completed NCT04178421 - Computerized Eye-tracking Attention Training for Children With Special Needs N/A
Completed NCT02985749 - A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder Phase 3
Recruiting NCT06012903 - Lower Urinary Tract Symptoms and School Functioning in Children
Not yet recruiting NCT04418921 - Improving Self-regulation in Children With Neurodevelopmental Disorders: N/A
Completed NCT01931033 - An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders N/A
Recruiting NCT04899544 - Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism N/A
Active, not recruiting NCT01932515 - Diagnostic Instruments for Autism in Deaf Children Study N/A
Recruiting NCT06188429 - Peripheral Blood VA/TREM2 Levels and Their Correlation Analysis With the Development and Autistic Symptoms in Children With ASD
Completed NCT06209463 - Posture, Hand Functions and Sensory Processing Skills on Nutrition
Recruiting NCT06155201 - Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders N/A
Recruiting NCT03502239 - Cognitive Rehabilitation (Mega Team) and Its Effects on Emotional and Behavioral Regulation in ADHD, ASD, and CHD N/A
Withdrawn NCT03829878 - Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) Phase 2
Recruiting NCT02461446 - Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
Completed NCT03900923 - Cannabidiol for ASD Open Trial Phase 2
Recruiting NCT06339359 - A Pilot Study to Develop a Behavior-based Screening Protocol for Early Diagnosis of Autism Spectrum Disorders
Completed NCT03099239 - hCT-MSCs for Children With Autism Spectrum Disorder (ASD) Phase 1
Terminated NCT05733390 - A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder Phase 2